Mammotome is committed to advancing technology to help clinicians accurately diagnose breast disease， such as breast cancer， through minimally invasive procedures. As the global market leader in vacuum-assisted breast biopsy， Mammotome has offered physicians and women a wide range of options and diagnostic tools since 1995. The Mammotome Biopsy System is a complete system for breast tissue sampling and management. Compatible with multiple imaging modalities， the Mammotome Biopsy System enables breast biopsy to be performed under stereotactic x-ray， ultrasound， MRI or molecular imaging guidance. Mammotome offers a full array of tissue markers to mark the biopsy site for follow-up observations. With the Mammotome Biopsy System， clinicians can achieve diagnostic confidence using a less invasive approach that offers women faster recovery， less scarring and lower costs of care as compared to open procedures. More than 3 million women worldwide have had an image-guided， minimally invasive breast biopsy using the Mammotome Biopsy System.